Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP961797priorityCriticalpatent/ECSP961797A/en
Publication of ECSP961797ApublicationCriticalpatent/ECSP961797A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La invención se refiere a una formulación de vacuna para la prevención de infecciones por Haemophilus Influenzae Tipo B (Hib) y en la que el antígeno está absorbido sobre fosfato de aluminio. La invención se refiere además a una vacuna multivalente, es decir una vacuna para el alivio o tratamiento de más de un estado de enfermedad. La presente invención también se refiere a la producción y uso de tales vacunas en medicina.The invention relates to a vaccine formulation for the prevention of Haemophilus Influenzae Type B (Hib) infections and in which the antigen is absorbed on aluminum phosphate. The invention further relates to a multivalent vaccine, i.e. a vaccine for the relief or treatment of more than one disease state. The present invention also relates to the production and use of such vaccines in medicine.
ECSP9617971996-06-201996-06-20
VACCINES INCLUDING AN ANTIGEN CONJUGATE POLYSACCHARIDE
ECSP961797A
(en)
COMPOSITION OF A COMBINED VACCINE INCLUDING A CAPSULAR POLYSACCHARIDE OF HAEMOPHILUS INFLUENZAE B CONJUGATED WITH A CARRIER PROTEIN ADSORBED ON ALUMINUM PHOSPHATE AND ONE OR OTHER DIFFERENT ANTIGENS FOR A DIFFERENT PRODUCTION
Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use
Multivalent immunogenic composition, and, process to stimulate the immune system to produce an immunogenic response to the human rotavirus serotype antigen vp7 without low-level transient fever
POLYPEPTIDE, VACCINE COMPOSITION, USE OF POLYPEPTIDE IN THE MANUFACTURE OF A COMPOSITION, AND METHOD TO PRODUCE AN IMMUNO-PROTECTIVE RESPONSE AGAINST HELICOBACTER PYLORI INFECTION